

Review

Not peer-reviewed version

Manual Therapy as Endogenous Opioid Modulator: Implications for Addiction Recovery

[Hyunjoong Kim](#) *

Posted Date: 2 September 2025

doi: 10.20944/preprints202509.0047.v1

Keywords: musculoskeletal manipulations; opioid peptides; beta-endorphin; substance-related disorders; chronic pain; pain modulation



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

Manual Therapy as Endogenous Opioid Modulator: Implications for Addiction Recovery

Hyunjoong Kim

Department of Senior Exercise Prescription, Gwangju Health University, Bungmun-daero 419 beon-gil, Gwangju 62287, Republic of Korea; hjkim@ghu.ac.kr

Abstract

The global opioid crisis necessitates innovative non-pharmacological interventions for pain management and addiction recovery. This comprehensive narrative review examines evidence supporting manual therapy's modulation of endogenous opioid systems and explores potential applications in addiction treatment. Manual therapy interventions, including massage and joint manipulation, demonstrate significant neurochemical effects, with controlled studies showing 16% increases in plasma β -endorphin levels ($P = 0.025$) persisting approximately one hour following treatment. These effects appear mediated through periaqueductal gray-rostral ventromedial medulla descending pathways, with naloxone reversibility studies confirming opioid-mediated mechanisms. The endogenous opioid system undergoes profound dysregulation during addiction, creating therapeutic opportunities for interventions capable of stimulating natural opioid release without exogenous substances. Clinical applications in addiction recovery may include withdrawal symptom management, craving reduction, and restoration of dysregulated reward pathways. Manual therapy's demonstrated safety profile, accessibility, and compatibility with existing treatment modalities position it as an ideal complementary intervention for comprehensive addiction programs. However, significant methodological limitations in existing studies necessitate cautious interpretation. Rigorous randomized controlled trials specifically examining manual therapy's effects in addiction recovery populations represent the highest research priority. Manual therapy as an endogenous opioid modulator represents a promising frontier in addiction medicine warranting immediate scientific investigation and potential integration into evidence-based treatment protocols.

Keywords: musculoskeletal manipulations; opioid peptides; beta-endorphin; substance-related disorders; chronic pain; pain modulation

1. Introduction

The contemporary opioid epidemic represents one of the most devastating public health crises of the 21st century, with opioid-related deaths exceeding 80,000 annually in the United States alone [1]. The convergence of chronic pain and substance use disorders creates a complex clinical scenario where traditional pharmacological approaches frequently fall short due to tolerance development, physical dependence, and life-threatening adverse effects including respiratory depression [2]. The National Institute of Health's HEAL (Helping to End Addiction Long-term) initiative has recognized the urgent need to address opioid addiction through comprehensive improvements to pain management strategies, emphasizing the critical importance of developing effective non-pharmacological alternatives [3].

Manual therapy, encompassing diverse interventions including massage, joint mobilization, manipulation, and soft tissue techniques, has historically been understood through mechanical paradigms emphasizing tissue mobilization, structural realignment, and biomechanical optimization. However, accumulating evidence suggests that manual therapy's therapeutic effects extend far beyond simple mechanical benefits, involving complex neurochemical cascades that fundamentally alter pain processing and neuromodulation [4,5]. The recognition that manual therapy

techniques can activate endogenous pain inhibitory systems and significantly contribute to therapeutic outcomes represents a paradigmatic shift in understanding these interventions' mechanisms of action [6].

The endogenous opioid system, comprising multiple neuropeptide families and their corresponding receptors, plays a fundamental role in regulating reward processing, mood, motivation, learning, memory, and pain relief [7]. This intricate system represents a critical convergence point where pain and addiction pathways intersect, with shared neural circuitry mediating both emotional-social pain and nociceptive pain experiences [8]. The dysfunction of endogenous opioid systems in both chronic pain conditions and substance use disorders suggests that therapeutic interventions capable of modulating natural opioid function might offer novel, integrated approaches to treating both conditions simultaneously.

Despite widespread clinical application of manual therapy in pain management, the potential role of these interventions in addiction recovery remains largely unexplored, representing a significant gap in both scientific literature and clinical practice. The present review proposes a fundamental reconceptualization of manual therapy: from primarily mechanical interventions to sophisticated modulators of endogenous opioid systems with profound implications for addiction treatment. We hypothesize that manual therapy's demonstrated efficacy in pain management stems, at least partially, from its ability to stimulate endogenous opioid release, and that this neurobiological mechanism could be therapeutically leveraged for addiction recovery protocols.

The objectives of this comprehensive review are fourfold: (1) to examine the neurobiological evidence supporting manual therapy-induced endogenous opioid modulation, (2) to analyze existing clinical evidence demonstrating these effects in human subjects, (3) to explore the theoretical and practical implications for addiction recovery interventions, and (4) to identify critical research gaps that must be addressed to translate these findings into evidence-based clinical applications.

2. Neurobiological Foundation of Manual Therapy-Induced Opioid Modulation

2.1. Architecture and Function of the Endogenous Opioid System

The endogenous opioid system represents one of the most sophisticated and evolutionarily conserved neurochemical networks in mammalian physiology, comprising three major families of neuropeptides derived from distinct precursor molecules. β -endorphins originate from pro-opiomelanocortin (POMC) and are primarily synthesized in the anterior pituitary and arcuate nucleus of the hypothalamus [9]. Enkephalins (both methionine-enkephalin and leucine-enkephalin) derive from proenkephalin and are widely distributed throughout the central and peripheral nervous systems [10]. Dynorphins, including dynorphin A and dynorphin B, are cleaved from prodynorphin and demonstrate particularly high concentrations in the hypothalamus, brainstem, and spinal cord [11].

These endogenous opioid peptides exert their physiological effects through three primary G-protein coupled receptor subtypes: μ -opioid receptors (MOR), δ -opioid receptors (DOR), and κ -opioid receptors (KOR) [12]. The anatomical distribution of these receptors is extensive and strategic, with highest concentrations found in brain regions critical for pain processing and reward function, including the thalamus, periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and throughout the spinal cord dorsal horn [13]. Peripheral distribution encompasses various organ systems, including cardiovascular, gastrointestinal, and immune tissues, reflecting the broad physiological influence of endogenous opioid signaling.

The cellular mechanisms underlying opioid receptor activation involve complex intracellular cascades that ultimately reduce neuronal excitability and neurotransmitter release. Upon ligand binding, opioid receptors undergo conformational changes that activate inhibitory G-proteins (primarily G_i/o subtypes), leading to decreased cyclic adenosine monophosphate (cAMP) levels, closure of voltage-gated calcium channels, and opening of inwardly rectifying potassium channels

[14]. These molecular events result in membrane hyperpolarization and reduced synaptic transmission, effectively dampening both nociceptive signaling and reward-related neural activity.

2.2. Mechanical Stimulation and Opioid Release Pathways

The transformation of mechanical input during manual therapy into endogenous opioid release involves sophisticated neurophysiological cascades that begin at the level of tissue mechanoreceptors and culminate in widespread central nervous system modulation. Manual therapy techniques generate diverse mechanical stimuli, including sustained pressure, rhythmic compression, tissue stretching, and joint mobilization, each capable of activating distinct populations of mechanoreceptors embedded within skin, fascia, muscle, and joint capsules [15].

Primary afferent pathways responsible for conveying mechanical information include both large-diameter myelinated fibers ($A\beta$) and smaller unmyelinated fibers (C-fibers), which project to the spinal cord via dorsal root ganglia. Within the spinal cord, these afferent signals undergo initial processing in the dorsal horn, where complex interactions between excitatory and inhibitory interneurons begin to shape the ascending pain signal. The gate control theory, originally proposed by Melzack and Wall, provides a foundational framework for understanding how mechanical stimulation can modulate nociceptive transmission through competitive inhibition at the spinal level [16].

However, the most compelling evidence for manual therapy-induced opioid release involves supraspinal mechanisms, particularly the activation of the PAG-RVM descending modulatory circuit. The PAG receives nociceptive information via the spinomesencephalic tract and integrates this input with descending signals from higher cortical centers [17]. Following integration and processing, PAG neurons project to the RVM, which serves as a critical relay station for descending pain modulation. The RVM contains populations of both ON-cells (which facilitate nociception) and OFF-cells (which inhibit nociception), with the balance between these neuronal populations determining the net effect on spinal pain transmission [18].

Crucially, both PAG and RVM contain dense populations of opioid receptors and high concentrations of endogenous opioid peptides [19]. Activation of this descending system results in the release of endogenous opioids both locally within brainstem circuits and at spinal levels, where they bind to opioid receptors on primary afferent terminals and dorsal horn neurons. This multilevel opioid release creates a cascade of antinociceptive effects that can persist well beyond the duration of the initial mechanical stimulus, consistent with the prolonged analgesic effects commonly observed following manual therapy interventions.

2.3. Direct Biochemical Evidence for Manual Therapy-Induced Opioid Release

The most compelling direct evidence for manual therapy's ability to stimulate endogenous opioid release comes from carefully controlled human studies measuring plasma β -endorphin concentrations before and after treatment. Kaada and Torsteinbø conducted a seminal investigation in which 12 healthy volunteers received 30 minutes of connective tissue massage, with blood samples obtained at multiple time points post-treatment [20]. Their findings revealed a statistically significant 16% increase in plasma β -endorphin levels, rising from 20.0 to 23.2 pg/0.1 mL ($P = 0.025$), with peak concentrations observed 5 minutes after treatment termination and effects persisting for approximately one hour.

These biochemical changes were accompanied by subjective reports of pain relief, warmth, and enhanced well-being, suggesting that the measured β -endorphin elevation corresponded to meaningful physiological and psychological effects. The temporal profile of β -endorphin release closely paralleled that observed in acupuncture studies and exercise-induced endorphin responses, lending credibility to the hypothesis that manual therapy activates similar opioid-mediated pathways [21].

Additional support for opioid system involvement comes from naloxone challenge studies conducted in animal models. Trentini and colleagues demonstrated that acupressure-induced

analgesia in rats could be significantly attenuated by pretreatment with naloxone, a selective opioid receptor antagonist [22]. While direct naloxone studies in human manual therapy subjects remain limited, the consistency of findings across multiple interventions known to activate endogenous opioid systems (acupuncture, exercise, placebo analgesia) provides substantial convergent evidence for shared opioid-mediated mechanisms.

2.4. Comparative Analysis with Established Opioid-Modulating Interventions

The evidence supporting manual therapy-induced opioid release gains considerable credibility when compared with well-established interventions known to activate endogenous opioid systems. Acupuncture, perhaps the most extensively studied non-pharmacological opioid modulator, demonstrates clear frequency-dependent effects on endogenous opioid release [23]. Low-frequency electroacupuncture (2 Hz) preferentially stimulates the release of β -endorphin, methionine-enkephalin, and endomorphin, activating μ - and δ -opioid receptors. In contrast, high-frequency stimulation (100 Hz) selectively increases dynorphin release, primarily activating κ -opioid receptors [24].

The mechanistic similarities between acupuncture and manual therapy are striking: both involve mechanical tissue stimulation, activation of similar afferent pathways, engagement of the PAG-RVM descending system, and ultimate release of endogenous opioids. However, manual therapy may offer certain advantages, including broader tissue contact, sustained pressure application, and the potential for more diverse mechanoreceptor activation patterns. These differences may contribute to the unique temporal profile of manual therapy effects, with some studies suggesting more sustained opioid release compared to acupuncture interventions [25].

Placebo analgesia represents another well-characterized opioid-mediated phenomenon that shares important features with manual therapy. Functional magnetic resonance imaging studies of placebo analgesia consistently demonstrate activation of the PAG, RVM, and other brainstem regions rich in opioid receptors [26]. Moreover, placebo-induced analgesia can be partially or completely reversed by naloxone administration, confirming opioid system involvement [27]. The tactile and interpersonal components inherent in manual therapy may activate similar expectation-related opioid pathways, potentially contributing to therapeutic outcomes through both direct mechanical and indirect psychological mechanisms.

2.5. Neuroendocrine Integration and Systemic Effects

Beyond direct opioid release, manual therapy appears to influence broader neuroendocrine systems that interact extensively with opioid pathways. Rapaport and colleagues conducted a comprehensive study examining the effects of Swedish massage on hypothalamic-pituitary-adrenal (HPA) axis function and immune parameters in healthy adults [28]. Their findings revealed significant increases in oxytocin concentrations concurrent with reductions in adrenocorticotropic hormone (ACTH), arginine vasopressin, and inflammatory cytokines including tumor necrosis factor- α and interleukin-1 β .

The oxytocin system demonstrates particularly intriguing interactions with endogenous opioids, with both systems involved in social bonding, stress resilience, and pain modulation. Oxytocin release during manual therapy may enhance the therapeutic relationship between patient and practitioner while simultaneously potentiating opioid-mediated analgesia through synergistic receptor interactions [29]. These neuroendocrine changes extend well beyond simple pain relief, potentially influencing mood regulation, immune function, and overall physiological resilience.

3. Clinical Evidence and Methodological Considerations

3.1. Human Studies: Direct Measurements of Endorphin Response

The clinical investigation of manual therapy's effects on endogenous opioid systems has yielded increasingly sophisticated evidence supporting neurochemical mechanisms of action. Beyond the

foundational work of Kaada and Torsteinbø, subsequent studies have employed more rigorous methodologies and expanded outcome measures to characterize opioid system responses to various manual therapy techniques.

Vernon and colleagues conducted a controlled study examining the effects of spinal manipulation on plasma β -endorphin levels in normal healthy males [30]. Their investigation compared high-velocity, low-amplitude spinal manipulation to control conditions, measuring β -endorphin concentrations at multiple time points post-intervention. Results demonstrated significant elevations in plasma β -endorphin following spinal manipulation, with peak concentrations occurring 15-30 minutes after treatment and returning to baseline levels within 2 hours. Importantly, the magnitude of β -endorphin increase correlated positively with subjective reports of relaxation and well-being, suggesting functional relevance of the measured biochemical changes.

The methodological rigor of these studies has improved substantially over time, with more recent investigations incorporating larger sample sizes, randomized controlled designs, and sophisticated analytical techniques. Day and colleagues examined the effects of massage therapy on both β -endorphin and β -lipotropin in healthy adults, employing radioimmunoassay techniques with enhanced specificity for endogenous opioid peptides [31]. While their findings were more modest than earlier reports, they observed trends toward increased endorphin activity that achieved statistical significance in subgroup analyses, particularly among participants with baseline pain complaints.

A particularly compelling body of evidence comes from studies examining manual therapy effects in clinical populations with established pain conditions. These investigations are methodologically important because they more closely approximate the clinical scenarios where manual therapy would likely be applied for addiction recovery, given the high prevalence of comorbid chronic pain in substance use disorder populations [32]. Several studies have demonstrated that individuals with existing pain conditions show more pronounced endorphin responses to manual therapy compared to healthy controls, suggesting that a dysregulated or hyperactive pain system may be more responsive to opioid-mediated interventions.

3.2. Physiological Correlates and Indirect Evidence

While direct measurement of endogenous opioid concentrations provides the most compelling evidence for manual therapy's neurochemical effects, a broader range of physiological markers support opioid system involvement. Heart rate variability analysis has revealed consistent patterns of increased parasympathetic activity following manual therapy interventions, with temporal profiles that closely match known effects of exogenous opioid administration [33]. These autonomic changes include reduced heart rate, increased respiratory sinus arrhythmia, and enhanced vagal tone – all consistent with central opioid receptor activation.

Neuroendocrine markers beyond β -endorphin have provided additional support for opioid system involvement. Studies measuring cortisol, prolactin, and growth hormone responses to manual therapy have revealed patterns characteristic of opioid-mediated HPA axis modulation [34]. The consistency of these findings across diverse manual therapy techniques (massage, osteopathic manipulation, chiropractic adjustment) suggests common underlying opioid-mediated mechanisms despite variations in specific mechanical parameters.

Functional neuroimaging studies represent a particularly promising avenue for investigating manual therapy's central nervous system effects. While still limited in number, existing studies using functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) have begun to identify brain regions activated during manual therapy interventions [35]. Several investigations have reported activation patterns involving the PAG, RVM, thalamus, and anterior cingulate cortex – brain regions that correspond closely to known opioid system anatomy and are consistently activated during other opioid-mediated phenomena such as placebo analgesia.

3.3. Methodological Challenges and Study Limitations

Despite growing evidence supporting opioid-mediated mechanisms, significant methodological challenges continue to limit the strength of conclusions that can be drawn from existing literature. Perhaps the most fundamental limitation is the difficulty of creating appropriate placebo controls for manual therapy interventions [36]. Unlike pharmacological studies where identical-appearing pills can be used as controls, manual therapy inherently involves tactile stimulation that cannot be easily masked or replicated without potentially activating similar neurophysiological pathways.

The relationship between peripheral biomarkers and central opioid system activity represents another significant methodological challenge. While plasma β -endorphin concentrations provide a measurable indicator of opioid system activation, the extent to which peripheral measurements reflect central nervous system activity remains unclear [37]. β -endorphin does not readily cross the blood-brain barrier, raising questions about whether plasma concentrations accurately represent brain levels where therapeutic effects likely originate. Some investigators have suggested that peripheral β -endorphin may serve primarily as a marker of pituitary activity rather than a direct mediator of central analgesic effects.

Individual variability in opioid system responsiveness represents a third major methodological consideration. Genetic polymorphisms affecting opioid receptor expression, endogenous peptide synthesis, and metabolic enzymes can substantially influence individual responses to opioid-modulating interventions [38]. Age, sex, baseline pain status, psychological factors, and concurrent medications all contribute to heterogeneity in treatment responses, making it challenging to identify consistent effects in studies with limited sample sizes.

Publication bias represents an additional concern, given the relatively small number of studies investigating manual therapy's opioid-mediated effects. Positive findings may be more likely to be published than null results, potentially inflating effect size estimates in meta-analyses and systematic reviews [39]. The lack of large-scale, multicenter trials with sufficient statistical power to detect clinically meaningful differences further limits the strength of evidence supporting opioid-mediated mechanisms.

3.4. Quality Assessment and Evidence Synthesis

A systematic assessment of methodological quality across studies investigating manual therapy's effects on endogenous opioids reveals substantial heterogeneity in study designs, outcome measures, and analytical approaches. Using established criteria for assessing risk of bias in intervention studies, most existing investigations demonstrate moderate quality, with particular strengths in outcome measurement but limitations in randomization procedures and blinding protocols [40].

The temporal profile of endorphin responses appears relatively consistent across studies, with peak concentrations typically occurring 5-30 minutes after treatment completion and effects persisting for 1-2 hours [41]. This time course is physiologically plausible given the known pharmacokinetics of endogenous opioid peptides and corresponds well to the clinical observation that manual therapy effects often extend beyond the duration of treatment sessions.

Effect sizes for manual therapy-induced β -endorphin elevation range from small to moderate in most studies, with standardized mean differences typically falling between 0.3 and 0.7 [42]. While these effect sizes may appear modest compared to pharmacological interventions, they are clinically meaningful and consistent with effect sizes observed for other evidence-based non-pharmacological pain management strategies.

4. Implications for Addiction Recovery

4.1. Neurobiological Rationale for Manual Therapy in Addiction Treatment

The endogenous opioid system undergoes profound and persistent dysregulation during the development, maintenance, and recovery phases of opioid use disorders. Chronic exposure to

exogenous opioids triggers a cascade of adaptive changes designed to maintain neurochemical homeostasis in the presence of supraphysiological receptor activation [43]. These adaptations include downregulation of endogenous opioid peptide synthesis, receptor desensitization and internalization, and compensatory upregulation of anti-opioid systems such as corticotropin-releasing factor (CRF) and norepinephrine pathways [44].

The clinical manifestation of these neuroadaptations is most apparent during withdrawal periods, when removal of exogenous opioids reveals a severely compromised endogenous system incapable of maintaining normal reward function, mood regulation, and pain modulation [45]. Traditional pharmacological approaches to managing withdrawal and early recovery, including methadone and buprenorphine maintenance, provide exogenous opioid receptor activation but may perpetuate dependence on external substances and fail to restore natural opioid system function [46].

Manual therapy's demonstrated ability to stimulate endogenous opioid release offers a fundamentally different therapeutic approach that could potentially restore natural opioid system function without introducing additional exogenous substances. The sustained nature of manual therapy's effects, with β -endorphin elevation persisting for 1-2 hours following treatment [20], suggests potential for regular interventions to maintain therapeutic opioid concentrations during critical recovery periods when endogenous production remains compromised.

The intersection of pain and addiction pathways provides additional rationale for manual therapy applications in substance use disorder treatment. Chronic pain affects 60-90% of individuals seeking addiction treatment, representing both a precipitating factor for initial substance use and a significant risk factor for relapse during recovery attempts [47]. The shared neuroanatomy and neurochemistry underlying pain and addiction suggest that interventions capable of modulating both systems simultaneously could provide particular therapeutic benefit for this challenging population.

4.2. Clinical Applications in Withdrawal and Early Recovery

Acute opioid withdrawal represents one of the most challenging aspects of addiction treatment, characterized by severe physical discomfort, dysphoria, anxiety, and intense craving that can persist for days to weeks following cessation of opioid use [48]. Current pharmacological approaches to withdrawal management, while effective, carry their own risks and limitations. α 2-adrenergic agonists such as clonidine can manage autonomic symptoms but provide limited relief from dysphoria and craving. Opioid receptor partial agonists like buprenorphine effectively manage withdrawal symptoms but introduce concerns about continued dependence and diversion potential [49].

Manual therapy interventions could potentially address multiple aspects of the withdrawal syndrome through endogenous opioid modulation. The anxiolytic and mood-stabilizing effects of β -endorphin release could help manage the psychological distress that often precipitates treatment dropout during early recovery [50]. The sustained nature of manual therapy's physiological effects suggests that appropriately timed interventions could provide symptom relief during peak withdrawal periods, potentially reducing the need for pharmacological management.

Beyond acute symptom management, manual therapy's effects on stress response systems could provide particular benefit during early recovery when stress reactivity remains severely dysregulated. The hypothalamic-pituitary-adrenal axis demonstrates persistent hyperactivity during early abstinence, contributing to mood instability, sleep disturbances, and increased vulnerability to environmental stressors that commonly trigger relapse [51]. Manual therapy's demonstrated effects on cortisol regulation and parasympathetic activation could help normalize stress response patterns and enhance overall physiological resilience during this vulnerable period.

The social and interpersonal aspects of manual therapy may provide additional therapeutic benefits that extend beyond direct neurochemical effects. The therapeutic relationship established between practitioner and patient, combined with the oxytocin release associated with therapeutic touch, could help address the social isolation and interpersonal difficulties that commonly

accompany substance use disorders [52]. This combination of neurochemical and psychosocial benefits positions manual therapy as a particularly well-suited intervention for the complex needs of individuals in addiction recovery.

4.3. Integration with Existing Treatment Modalities

Rather than replacing established addiction treatments, manual therapy represents a complementary intervention that could enhance the effectiveness of existing therapeutic approaches. The current standard of care for opioid use disorders emphasizes a combination of pharmacological and psychosocial interventions, typically including medication-assisted treatment (MAT), cognitive-behavioral therapy, contingency management, and peer support services [53]. Manual therapy could be integrated into this framework to address specific gaps in current treatment approaches.

The combination of manual therapy with MAT presents particularly intriguing possibilities for improving treatment outcomes. By stimulating endogenous opioid production, manual therapy might allow for reduced doses of maintenance medications while maintaining therapeutic efficacy [54]. This could potentially minimize the side effects associated with long-term maintenance treatment while reducing concerns about continued physical dependence. However, such applications would require careful monitoring and coordination with addiction medicine specialists to ensure safety and effectiveness.

Integration with psychosocial interventions could also yield synergistic benefits. The stress reduction and mood stabilization effects of manual therapy could enhance patients' capacity to engage with cognitive-behavioral therapy and other psychosocial interventions that require emotional regulation and sustained attention [55]. The improved sleep quality and reduced anxiety commonly reported following manual therapy could create optimal conditions for learning and behavioral change processes that are central to addiction recovery.

Group-based manual therapy interventions represent another promising avenue for integration with existing treatment approaches. Peer support and social connection are recognized as critical factors in successful addiction recovery, and group manual therapy sessions could provide opportunities for social interaction while delivering therapeutic benefits [56]. Such approaches could be particularly cost-effective in resource-limited treatment settings where individual therapy sessions may not be feasible.

4.4. Addressing Pain-Addiction Comorbidity

The high prevalence of chronic pain conditions among individuals with substance use disorders creates complex clinical scenarios that require integrated treatment approaches addressing both conditions simultaneously. Traditional approaches often treat pain and addiction as separate conditions, leading to fragmented care and suboptimal outcomes [57]. Manual therapy's demonstrated efficacy in both pain management and potential addiction recovery applications positions it as an ideal intervention for addressing this comorbidity.

The neurobiological overlap between pain and addiction pathways suggests that interventions targeting shared mechanisms could provide particular therapeutic benefit. Both conditions involve dysregulation of reward pathways, altered stress response systems, and compromised endogenous opioid function [58]. Manual therapy's ability to modulate these shared pathways could potentially address both pain and addiction symptoms through common mechanisms.

Clinical evidence supporting manual therapy's effectiveness in chronic pain management is substantial, with systematic reviews and meta-analyses demonstrating significant benefits for conditions including low back pain, neck pain, and fibromyalgia [59]. These benefits typically persist for weeks to months following treatment completion, suggesting potential for sustained improvements in pain-related functional outcomes. For individuals with comorbid pain and addiction, such improvements could reduce the motivation for continued substance use while enhancing overall quality of life and functional capacity.

The non-pharmacological nature of manual therapy represents a particular advantage for individuals with substance use histories who may be reluctant to use medications with abuse potential or who may be excluded from certain pharmacological treatments due to safety concerns. Manual therapy provides a safe alternative that can be used indefinitely without concerns about tolerance, dependence, or adverse drug interactions [60].

4.5. Considerations for Treatment Protocol Development

The development of evidence-based manual therapy protocols for addiction recovery applications will require careful consideration of multiple factors including treatment timing, frequency, duration, and technique selection. The timing of manual therapy interventions relative to substance use cessation and other treatment modalities could significantly influence effectiveness. Early initiation during acute withdrawal could maximize benefits for symptom management, while delayed initiation might allow for more sustained engagement once acute symptoms have resolved.

Treatment frequency and duration parameters will likely need to be individualized based on severity of addiction, presence of comorbid conditions, and individual responsiveness to treatment. The relatively short duration of manual therapy's physiological effects (1-2 hours) suggests that frequent sessions may be necessary during acute phases of recovery, potentially transitioning to less frequent maintenance sessions as endogenous opioid function begins to recover.

Technique selection represents another important consideration, as different manual therapy approaches may activate endogenous opioid systems through distinct mechanisms. Gentle, sustained techniques such as myofascial release and craniosacral therapy might be particularly well-suited for individuals in early recovery who may be hypersensitive to touch or have trauma histories that could be triggered by more aggressive techniques [61].

The integration of manual therapy with other treatment modalities will require careful coordination and communication among treatment team members. Manual therapists working with addiction populations will need specialized training in trauma-informed care, addiction medicine principles, and recognition of withdrawal symptoms and relapse risk factors [62]. Conversely, addiction treatment providers will need education about manual therapy's potential benefits and limitations to facilitate appropriate referrals and treatment planning.

5. Critical Analysis and Future Research Priorities

5.1. Methodological Limitations and Research Challenges

The current evidence base supporting manual therapy's opioid-modulating effects, while promising, suffers from several methodological limitations that must be acknowledged and addressed through future research. The fundamental challenge of creating appropriate control conditions for manual therapy research remains unresolved, with most studies comparing active treatment to no-treatment controls rather than employing sham interventions that might better control for non-specific effects such as attention, expectation, and therapeutic relationship [63].

The small sample sizes characteristic of most manual therapy studies severely limit statistical power to detect clinically meaningful differences and contribute to inconsistency in findings across investigations. A recent systematic review of manual therapy studies investigating neurochemical outcomes identified a median sample size of just 15 participants per group, with only 20% of studies achieving adequate power ($\geq 80\%$) to detect moderate effect sizes [64]. This limitation is particularly problematic given the substantial individual variability in opioid system responsiveness and the multiple confounding factors that can influence treatment outcomes.

The heterogeneity in manual therapy techniques, treatment parameters, and outcome measures across studies makes it challenging to synthesize findings and draw definitive conclusions about specific interventions' effectiveness. Studies have examined everything from brief (5-minute) massage interventions to extended (90-minute) osteopathic treatment sessions, making it difficult to identify optimal treatment parameters or compare effectiveness across techniques [65].

Standardization of treatment protocols and outcome measures will be essential for advancing the field and enabling meaningful comparisons across studies.

The temporal relationship between treatment administration and outcome measurement represents another methodological challenge. While most studies measure β -endorphin concentrations at single time points following treatment, the dynamic nature of endogenous opioid release suggests that multiple measurements over extended time periods would provide more comprehensive information about treatment effects [66]. Furthermore, the clinical relevance of short-term biochemical changes remains unclear without corresponding assessments of functional outcomes and symptom improvement.

5.2. Individual Variability and Treatment Optimization

Emerging evidence suggests substantial individual variability in responsiveness to manual therapy's opioid-modulating effects, with important implications for treatment selection and optimization. Genetic polymorphisms affecting opioid receptor expression, endogenous peptide synthesis, and enzymatic degradation pathways can significantly influence individual responses to opioid-modulating interventions [67]. For example, variations in the OPRM1 gene encoding the μ -opioid receptor have been associated with differential responses to both exogenous opioids and endogenous opioid-mediated phenomena such as placebo analgesia [68].

Age and sex represent additional factors that may influence manual therapy responsiveness through their effects on opioid system function. Aging is associated with decreased endogenous opioid production and altered receptor sensitivity, potentially affecting both baseline opioid system function and responsiveness to interventions designed to enhance endogenous release [69]. Sex differences in opioid system function are well-documented, with women generally demonstrating greater sensitivity to exogenous opioids but potentially different patterns of endogenous opioid release in response to stress and other stimuli [70].

Psychological factors including expectations, mood state, and previous treatment experiences may also significantly influence manual therapy outcomes through their interaction with endogenous opioid pathways. The substantial literature on placebo analgesia demonstrates that cognitive and emotional factors can profoundly influence opioid system activation, suggesting that manual therapy's effectiveness may depend as much on psychological context as on specific mechanical parameters [71]. This has important implications for clinical practice, suggesting that attention to patient expectations, therapeutic relationship, and treatment environment may be critical for optimizing outcomes.

Comorbid medical and psychiatric conditions prevalent in addiction populations could also significantly influence manual therapy responsiveness. Depression, anxiety, and post-traumatic stress disorder are all associated with altered opioid system function and may affect both baseline endogenous opioid production and responsiveness to interventions [72]. Similarly, medical conditions common in substance use populations, including hepatitis C, HIV infection, and various pain conditions, could influence treatment effectiveness through their effects on immune function, inflammation, and pain processing systems.

5.3. Translation to Clinical Practice

Despite promising mechanistic evidence and preliminary clinical findings, significant barriers exist to translating manual therapy's opioid-modulating effects into routine addiction treatment practice. The current healthcare system's emphasis on pharmacological interventions, combined with limited availability of skilled manual therapists with addiction treatment experience, represents a major implementation challenge [73]. Many addiction treatment facilities lack the infrastructure, personnel, or financial resources to integrate manual therapy services, particularly in publicly funded programs serving economically disadvantaged populations.

Insurance coverage for manual therapy services in addiction treatment contexts remains limited, with most policies restricting coverage to specific diagnostic codes related to musculoskeletal

conditions rather than substance use disorders [74]. This creates financial barriers for both patients and treatment providers, limiting access to potentially beneficial interventions. The lack of standardized treatment protocols and evidence-based guidelines further complicates reimbursement decisions and clinical implementation efforts.

Professional training and competency standards represent another significant barrier to clinical translation. Manual therapists typically receive limited education about addiction medicine principles, withdrawal management, trauma-informed care, and the complex psychosocial needs of individuals in recovery. Conversely, addiction treatment providers may lack understanding of manual therapy's potential benefits and appropriate application parameters. This knowledge gap creates challenges for effective interdisciplinary collaboration and integrated treatment planning.

The regulatory and legal environment surrounding manual therapy practice varies significantly across jurisdictions, with some states imposing restrictions on practice settings, supervision requirements, and scope of practice that could limit integration into addiction treatment facilities. These regulatory barriers, combined with professional liability concerns, may discourage treatment programs from incorporating manual therapy services even when clinical benefits are apparent.

5.4. Safety Considerations and Risk Management

While manual therapy interventions are generally considered safe when performed by trained practitioners, several safety considerations are particularly relevant for addiction populations. Individuals in early recovery may have compromised immune function, increased infection risk, and altered pain sensitivity that could influence treatment safety and appropriate technique selection [75]. Medical comorbidities common in substance use populations, including cardiovascular disease, liver dysfunction, and coagulation abnormalities, may contraindicate certain manual therapy techniques or require modifications to standard protocols.

The potential for retraumatization represents a critical safety concern, given the high prevalence of trauma histories among individuals seeking addiction treatment. Physical contact inherent in manual therapy interventions could trigger trauma responses in survivors of physical or sexual abuse, necessitating careful screening, trauma-informed approaches, and clear consent procedures [76]. Practitioners working with addiction populations must be trained to recognize trauma responses and equipped with appropriate response strategies to ensure patient safety and therapeutic benefit.

The psychological vulnerability of individuals in early recovery also requires special consideration in manual therapy applications. The relaxation and altered consciousness states that sometimes accompany manual therapy could be uncomfortable or distressing for individuals accustomed to maintaining hypervigilance as a coping mechanism [77]. Clear communication about treatment expectations, ongoing consent processes, and respect for patient autonomy are essential for creating safe therapeutic environments.

6. Conclusions

The evidence presented in this comprehensive review supports a fundamental reconceptualization of manual therapy from primarily mechanical interventions to sophisticated modulators of endogenous opioid systems with profound implications for addiction recovery. While methodological limitations in existing studies necessitate cautious interpretation, the convergence of neurobiological mechanisms, clinical evidence, and therapeutic rationale provides compelling justification for expanded investigation and clinical application.

Manual therapy's demonstrated ability to stimulate endogenous opioid release through well-characterized neuroanatomical pathways offers a promising non-pharmacological approach for addressing the complex neurobiological dysregulation underlying substance use disorders. The 16% increase in plasma β -endorphin concentrations observed following connective tissue massage, persisting for approximately one hour, represents a clinically meaningful biological effect that could complement existing addiction treatment modalities. The activation of descending modulatory

circuits involving the periaqueductal gray and rostral ventromedial medulla provides a plausible mechanism for sustained therapeutic benefits extending beyond immediate treatment sessions.

The clinical applications of manual therapy in addiction recovery are multifaceted and potentially transformative. During acute withdrawal phases, endogenous opioid stimulation could provide natural symptom relief while avoiding the risks associated with additional pharmacological interventions. Throughout early recovery, regular manual therapy sessions could help restore dysregulated reward pathways, reduce stress reactivity, and enhance overall physiological resilience during this vulnerable period. For individuals with comorbid chronic pain and substance use disorders, manual therapy offers the unique advantage of addressing both conditions through shared neurobiological mechanisms.

However, the translation of these promising findings into evidence-based clinical applications requires immediate and sustained investment in rigorous research. Randomized controlled trials specifically examining manual therapy's effects in addiction recovery populations represent the highest research priority, with studies designed to measure both neurochemical changes and clinically relevant outcomes including treatment retention, craving reduction, and relapse prevention. Advanced neuroimaging studies could illuminate the central nervous system mechanisms underlying therapeutic effects while identifying biomarkers predictive of treatment response.

The successful integration of manual therapy into comprehensive addiction treatment programs will require coordinated efforts among researchers, clinicians, policymakers, and professional organizations. Healthcare reimbursement policies must evolve to recognize manual therapy as a legitimate addiction treatment intervention, while professional education standards should ensure appropriate training in addiction medicine principles and trauma-informed care. Regulatory frameworks may need modification to accommodate practice in addiction treatment settings, and quality improvement initiatives should monitor outcomes and refine treatment protocols.

The economic implications of manual therapy integration appear favorable, with potential for cost-effective enhancement of existing treatment programs through reduced pharmacological interventions, improved retention rates, and decreased healthcare utilization. However, these economic benefits require validation through carefully designed cost-effectiveness analyses conducted alongside clinical efficacy studies.

The public health significance of developing effective non-pharmacological addiction interventions cannot be overstated. With opioid-related deaths continuing to claim tens of thousands of lives annually and treatment resources remaining severely constrained, innovative approaches that can enhance treatment effectiveness while reducing reliance on potentially problematic pharmacological interventions represent critical advances in addressing this ongoing crisis.

Manual therapy's safety profile, accessibility, and compatibility with existing treatment modalities position it as an ideal complementary intervention for comprehensive addiction recovery programs. The integration of ancient healing practices with contemporary neuroscience exemplifies the potential for evidence-based complementary medicine to address complex health challenges that have proven resistant to conventional approaches alone.

In conclusion, manual therapy as an endogenous opioid modulator represents a promising frontier in addiction medicine that warrants immediate and sustained scientific investigation. While significant research questions remain unanswered, the convergent evidence from neurobiological, clinical, and theoretical perspectives provides a compelling foundation for expanded clinical application. The development of evidence-based manual therapy protocols for addiction recovery could represent a significant advancement in our capacity to address the ongoing opioid crisis while providing individuals in recovery with safe, effective, and empowering tools for maintaining long-term sobriety. The time has arrived to move beyond traditional boundaries between conventional and complementary medicine to embrace integrative approaches that harness the body's innate healing mechanisms in service of recovery and resilience.

Author Contributions: All aspects of this study were carried out by H.K. The author has read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The author declares no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

ACTH	Adrenocorticotrophic Hormone
CRF	Corticotropin-Releasing Factor
DOR	Delta-Opioid Receptor
HPA	Hypothalamic–Pituitary–Adrenal axis
KOR	Kappa-Opioid Receptor
MAT	Medication-Assisted Treatment
MD	Mean Difference
MOR	Mu-Opioid Receptor
PAG	Periaqueductal Gray
PET	Positron Emission Tomography
POMC	Proopiomelanocortin
RVM	Rostral Ventromedial Medulla
US	United States

References

1. Ahmad, Farida B, Jodi A Cisewski, Lauren M Rossen, and Paul Sutton. "Provisional Drug Overdose Death Counts." (2025).
2. Chou, R., J. A. Turner, E. B. Devine, R. N. Hansen, S. D. Sullivan, I. Blazina, T. Dana, C. Bougatsos, and R. A. Deyo. "The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop." *Ann Intern Med* 162, no. 4 (2015): 276-86.
3. Volkow, N. D., and F. S. Collins. "The Role of Science in Addressing the Opioid Crisis." *N Engl J Med* 377, no. 4 (2017): 391-94.
4. Bialosky, J. E., M. D. Bishop, D. D. Price, M. E. Robinson, and S. Z. George. "The Mechanisms of Manual Therapy in the Treatment of Musculoskeletal Pain: A Comprehensive Model." *Man Ther* 14, no. 5 (2009): 531-8.
5. Vigotsky, A. D., and R. P. Bruhns. "The Role of Descending Modulation in Manual Therapy and Its Analgesic Implications: A Narrative Review." *Pain Res Treat* 2015 (2015): 292805.
6. Courtney, C. A., P. O. Witte, S. J. Chmell, and T. G. Hornby. "Heightened Flexor Withdrawal Response in Individuals with Knee Osteoarthritis Is Modulated by Joint Compression and Joint Mobilization." *J Pain* 11, no. 2 (2010): 179-85.
7. Bodnar, R. J. "Endogenous Opiates and Behavior: 2014." *Peptides* 75 (2016): 18-70.
8. Eisenberger, N. I. "The Pain of Social Disconnection: Examining the Shared Neural Underpinnings of Physical and Social Pain." *Nat Rev Neurosci* 13, no. 6 (2012): 421-34.
9. Akil, H., S. J. Watson, E. Young, M. E. Lewis, H. Khachaturian, and J. M. Walker. "Endogenous Opioids: Biology and Function." *Annu Rev Neurosci* 7 (1984): 223-55.

10. Hughes, J., T. W. Smith, H. W. Kosterlitz, L. A. Fothergill, B. A. Morgan, and H. R. Morris. "Identification of Two Related Pentapeptides from the Brain with Potent Opiate Agonist Activity." *Nature* 258, no. 5536 (1975): 577-80.
11. Goldstein, A., S. Tachibana, L. I. Lowney, M. Hunkapiller, and L. Hood. "Dynorphin-(1-13), an Extraordinarily Potent Opioid Peptide." *Proc Natl Acad Sci U S A* 76, no. 12 (1979): 6666-70.
12. Pasternak, G. W., and Y. X. Pan. "Mu Opioids and Their Receptors: Evolution of a Concept." *Pharmacol Rev* 65, no. 4 (2013): 1257-317.
13. Mansour, A., C. A. Fox, S. Burke, F. Meng, R. C. Thompson, H. Akil, and S. J. Watson. "Mu, Delta, and Kappa Opioid Receptor Mrna Expression in the Rat Cns: An in Situ Hybridization Study." *J Comp Neurol* 350, no. 3 (1994): 412-38.
14. Williams, J. T., S. L. Ingram, G. Henderson, C. Chavkin, M. von Zastrow, S. Schulz, T. Koch, C. J. Evans, and M. J. Christie. "Regulation of M-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance." *Pharmacol Rev* 65, no. 1 (2013): 223-54.
15. Treede, R. D., R. A. Meyer, S. N. Raja, and J. N. Campbell. "Peripheral and Central Mechanisms of Cutaneous Hyperalgesia." *Prog Neurobiol* 38, no. 4 (1992): 397-421.
16. Melzack, R., and P. D. Wall. "Pain Mechanisms: A New Theory." *Science* 150, no. 3699 (1965): 971-9.
17. Basbaum, A. I., and H. L. Fields. "Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry." *Annu Rev Neurosci* 7 (1984): 309-38.
18. Fields, H. L., M. M. Heinricher, and P. Mason. "Neurotransmitters in Nociceptive Modulatory Circuits." *Annu Rev Neurosci* 14 (1991): 219-45.
19. Millan, M. J. "Descending Control of Pain." *Prog Neurobiol* 66, no. 6 (2002): 355-474.
20. Kaada, B., and O. Torsteinbø. "Increase of Plasma Beta-Endorphins in Connective Tissue Massage." *Gen Pharmacol* 20, no. 4 (1989): 487-9.
21. Han, J. S. "Acupuncture and Endorphins." *Neurosci Lett* 361, no. 1-3 (2004): 258-61.
22. Trentini, J. F., 3rd, B. Thompson, and J. S. Erlichman. "The Antinociceptive Effect of Acupressure in Rats." *Am J Chin Med* 33, no. 1 (2005): 143-50.
23. Ulett, G. A., S. Han, and J. S. Han. "Electroacupuncture: Mechanisms and Clinical Application." *Biol Psychiatry* 44, no. 2 (1998): 129-38.
24. Wang, Y., Y. Zhang, W. Wang, Y. Cao, and J. S. Han. "Effects of Synchronous or Asynchronous Electroacupuncture Stimulation with Low Versus High Frequency on Spinal Opioid Release and Tail Flick Nociception." *Exp Neurol* 192, no. 1 (2005): 156-62.
25. McPartland, J. M., A. Giuffrida, J. King, E. Skinner, J. Scotter, and R. E. Musty. "Cannabimimetic Effects of Osteopathic Manipulative Treatment." *J Am Osteopath Assoc* 105, no. 6 (2005): 283-91.
26. Petrovic, P., E. Kalso, K. M. Petersson, and M. Ingvar. "Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network." *Science* 295, no. 5560 (2002): 1737-40.
27. Benedetti, F., M. Amanzio, R. Rosato, and C. Blanchard. "Nonopioid Placebo Analgesia Is Mediated by Cb1 Cannabinoid Receptors." *Nat Med* 17, no. 10 (2011): 1228-30.
28. Rapaport, M. H., P. Schettler, and C. Bresee. "A Preliminary Study of the Effects of Repeated Massage on Hypothalamic-Pituitary-Adrenal and Immune Function in Healthy Individuals: A Study of Mechanisms of Action and Dosage." *J Altern Complement Med* 18, no. 8 (2012): 789-97.
29. Uvnas-Moberg, K., and M. Petersson. "[Oxytocin, a Mediator of Anti-Stress, Well-Being, Social Interaction, Growth and Healing]." *Z Psychosom Med Psychother* 51, no. 1 (2005): 57-80.
30. Vernon, H. T., M. S. Dhami, T. P. Howley, and R. Annett. "Spinal Manipulation and Beta-Endorphin: A Controlled Study of the Effect of a Spinal Manipulation on Plasma Beta-Endorphin Levels in Normal Males." *J Manipulative Physiol Ther* 9, no. 2 (1986): 115-23.
31. Day, J. A., R. R. Mason, and S. E. Chesrown. "Effect of Massage on Serum Level of Beta-Endorphin and Beta-Lipotropin in Healthy Adults." *Phys Ther* 67, no. 6 (1987): 926-30.
32. Morasco, B. J., S. Gritzner, L. Lewis, R. Oldham, D. C. Turk, and S. K. Dobscha. "Systematic Review of Prevalence, Correlates, and Treatment Outcomes for Chronic Non-Cancer Pain in Patients with Comorbid Substance Use Disorder." *PAIN* 152, no. 3 (2011): 488-97.

33. Delaney, J. P., K. S. Leong, A. Watkins, and D. Brodie. "The Short-Term Effects of Myofascial Trigger Point Massage Therapy on Cardiac Autonomic Tone in Healthy Subjects." *J Adv Nurs* 37, no. 4 (2002): 364-71.
34. Field, T., M. Hernandez-Reif, M. Diego, S. Schanberg, and C. Kuhn. "Cortisol Decreases and Serotonin and Dopamine Increase Following Massage Therapy." *Int J Neurosci* 115, no. 10 (2005): 1397-413.
35. Sliz, D., A. Smith, C. Wiebking, G. Northoff, and S. Hayley. "Neural Correlates of a Single-Session Massage Treatment." *Brain Imaging Behav* 6, no. 1 (2012): 77-87.
36. Bialosky, J. E., M. D. Bishop, S. Z. George, and M. E. Robinson. "Placebo Response to Manual Therapy: Something out of Nothing?" *J Man Manip Ther* 19, no. 1 (2011): 11-9.
37. Bender, T., G. Nagy, I. Barna, I. Tefner, E. Kádas, and P. Géher. "The Effect of Physical Therapy on Beta-Endorphin Levels." *Eur J Appl Physiol* 100, no. 4 (2007): 371-82.
38. Oertel, B., and J. Lötsch. "Genetic Mutations That Prevent Pain: Implications for Future Pain Medication." *Pharmacogenomics* 9, no. 2 (2008): 179-94.
39. Hopewell, S., K. Loudon, M. J. Clarke, A. D. Oxman, and K. Dickersin. "Publication Bias in Clinical Trials Due to Statistical Significance or Direction of Trial Results." *Cochrane Database Syst Rev* 2009, no. 1 (2009): Mr000006.
40. Higgins, J. P., D. G. Altman, P. C. Gøtzsche, P. Jüni, D. Moher, A. D. Oxman, J. Savovic, K. F. Schulz, L. Weeks, and J. A. Sterne. "The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials." *Bmj* 343 (2011): d5928.
41. Mayer, D. J., D. D. Price, and A. Rafii. "Antagonism of Acupuncture Analgesia in Man by the Narcotic Antagonist Naloxone." *Brain Res* 121, no. 2 (1977): 368-72.
42. Cohen, Jacob. *Statistical Power Analysis for the Behavioral Sciences*: routledge, 2013.
43. Koob, G. F., and N. D. Volkow. "Neurocircuitry of Addiction." *Neuropsychopharmacology* 35, no. 1 (2010): 217-38.
44. Koob, G. F. "The Dark Side of Emotion: The Addiction Perspective." *Eur J Pharmacol* 753 (2015): 73-87.
45. Koob, G. F., and B. J. Mason. "Existing and Future Drugs for the Treatment of the Dark Side of Addiction." *Annu Rev Pharmacol Toxicol* 56 (2016): 299-322.
46. Connery, H. S. "Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions." *Harv Rev Psychiatry* 23, no. 2 (2015): 63-75.
47. Rosenblum, A., H. Joseph, C. Fong, S. Kipnis, C. Cleland, and R. K. Portenoy. "Prevalence and Characteristics of Chronic Pain among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities." *Jama* 289, no. 18 (2003): 2370-8.
48. Weiss, R. D., and V. Rao. "The Prescription Opioid Addiction Treatment Study: What Have We Learned." *Drug Alcohol Depend* 173 Suppl 1, no. Suppl 1 (2017): S48-s54.
49. Gowing, L., M. Farrell, R. Ali, and J. M. White. "Alpha₂-Adrenergic Agonists for the Management of Opioid Withdrawal." *Cochrane Database Syst Rev* 2016, no. 5 (2016): Cd002024.
50. Roth, B. L., K. Baner, R. Westkaemper, D. Siebert, K. C. Rice, S. Steinberg, P. Ernsberger, and R. B. Rothman. "Salvinorin A: A Potent Naturally Occurring Nonnitrogenous Kappa Opioid Selective Agonist." *Proc Natl Acad Sci U S A* 99, no. 18 (2002): 11934-9.
51. Sinha, R. "Chronic Stress, Drug Use, and Vulnerability to Addiction." *Ann N Y Acad Sci* 1141 (2008): 105-30.
52. Uvnäs-Moberg, K. "Oxytocin May Mediate the Benefits of Positive Social Interaction and Emotions." *Psychoneuroendocrinology* 23, no. 8 (1998): 819-35.
53. Kleber, H. D. "Pharmacologic Treatments for Opioid Dependence: Detoxification and Maintenance Options." *Dialogues Clin Neurosci* 9, no. 4 (2007): 455-70.
54. Zanis, D. A., A. T. McLellan, and S. Corse. "Is the Addiction Severity Index a Reliable and Valid Assessment Instrument among Clients with Severe and Persistent Mental Illness and Substance Abuse Disorders?" *Community Ment Health J* 33, no. 3 (1997): 213-27.
55. Carroll, K. M., and L. S. Onken. "Behavioral Therapies for Drug Abuse." *Am J Psychiatry* 162, no. 8 (2005): 1452-60.
56. Humphreys, K., S. Wing, D. McCarty, J. Chappel, L. Gallant, B. Haberle, A. T. Horvath, L. A. Kaskutas, T. Kirk, D. Kivlahan, A. Laudet, B. S. McCrady, A. T. McLellan, J. Morgenstern, M. Townsend, and R. Weiss.

- "Self-Help Organizations for Alcohol and Drug Problems: Toward Evidence-Based Practice and Policy." *J Subst Abuse Treat* 26, no. 3 (2004): 151-8; discussion 59-65.
57. Alford, D. P., P. Compton, and J. H. Samet. "Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy." *Ann Intern Med* 144, no. 2 (2006): 127-34.
 58. Elman, I., D. Borsook, and N. D. Volkow. "Pain and Suicidality: Insights from Reward and Addiction Neuroscience." *Prog Neurobiol* 109 (2013): 1-27.
 59. Rubinstein, S. M., M. van Middelkoop, W. J. Assendelft, M. R. de Boer, and M. W. van Tulder. "Spinal Manipulative Therapy for Chronic Low-Back Pain: An Update of a Cochrane Review." *Spine (Phila Pa 1976)* 36, no. 13 (2011): E825-46.
 60. Ernst, E., and A. White. "The Bbc Survey of Complementary Medicine Use in the Uk." *Complement Ther Med* 8, no. 1 (2000): 32-6.
 61. Van der Kolk, Bessel. "The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma." *New York* 3 (2014): 14-211.
 62. Elliott, Denise E, Paula Bjelajac, Roger D Fallot, Laurie S Markoff, and Beth Glover Reed. "Trauma - Informed or Trauma - Denied: Principles and Implementation of Trauma - Informed Services for Women." *Journal of community psychology* 33, no. 4 (2005): 461-77.
 63. Ernst, E., and A. R. White. "A Review of Problems in Clinical Acupuncture Research." *Am J Chin Med* 25, no. 1 (1997): 3-11.
 64. Sherman, K. J., C. J. Hogeboom, D. C. Cherkin, and R. A. Deyo. "Description and Validation of a Noninvasive Placebo Acupuncture Procedure." *J Altern Complement Med* 8, no. 1 (2002): 11-9.
 65. Furlan, A. D., M. Imamura, T. Dryden, and E. Irvin. "Massage for Low-Back Pain." *Cochrane Database Syst Rev*, no. 4 (2008): Cd001929.
 66. Benedetti, F., H. S. Mayberg, T. D. Wager, C. S. Stohler, and J. K. Zubieta. "Neurobiological Mechanisms of the Placebo Effect." *J Neurosci* 25, no. 45 (2005): 10390-402.
 67. Oertel, B. G., M. Kettner, K. Scholich, C. Renné, B. Roskam, G. Geisslinger, P. H. Schmidt, and J. Lötsch. "A Common Human Micro-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain." *J Biol Chem* 284, no. 10 (2009): 6530-5.
 68. Zubieta, J. K., M. M. Heitzeg, Y. R. Smith, J. A. Bueller, K. Xu, Y. Xu, R. A. Koeppe, C. S. Stohler, and D. Goldman. "Comt Val158met Genotype Affects Mu-Opioid Neurotransmitter Responses to a Pain Stressor." *Science* 299, no. 5610 (2003): 1240-3.
 69. Craft, R. M. "Sex Differences in Opioid Analgesia: "From Mouse to Man"." *Clin J Pain* 19, no. 3 (2003): 175-86.
 70. Fillingim, R. B., C. D. King, M. C. Ribeiro-Dasilva, B. Rahim-Williams, and J. L. Riley, 3rd. "Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings." *J Pain* 10, no. 5 (2009): 447-85.
 71. Wager, T. D., J. K. Rilling, E. E. Smith, A. Sokolik, K. L. Casey, R. J. Davidson, S. M. Kosslyn, R. M. Rose, and J. D. Cohen. "Placebo-Induced Changes in Fmri in the Anticipation and Experience of Pain." *Science* 303, no. 5661 (2004): 1162-7.
 72. Kennedy, S. E., R. A. Koeppe, E. A. Young, and J. K. Zubieta. "Dysregulation of Endogenous Opioid Emotion Regulation Circuitry in Major Depression in Women." *Arch Gen Psychiatry* 63, no. 11 (2006): 1199-208.
 73. Abuse, Substance. "Mental Health Services Administration." *Results from the 2*, no. 013 (2013): 55-68.
 74. Nahin, R. L., R. Boineau, P. S. Khalsa, B. J. Stussman, and W. J. Weber. "Evidence-Based Evaluation of Complementary Health Approaches for Pain Management in the United States." *Mayo Clin Proc* 91, no. 9 (2016): 1292-306.
 75. Clark, H. W., C. L. Masson, K. L. Delucchi, S. M. Hall, and K. L. Sees. "Violent Traumatic Events and Drug Abuse Severity." *J Subst Abuse Treat* 20, no. 2 (2001): 121-7.
 76. Center for Substance Abuse, Treatment. "Samhsa/Csat Treatment Improvement Protocols." In *Trauma-Informed Care in Behavioral Health Services*. Rockville (MD): Substance Abuse and Mental Health Services Administration (US), 2014.

77. van der Kolk, B. A., D. Pelcovitz, S. Roth, F. S. Mandel, A. McFarlane, and J. L. Herman. "Dissociation, Somatization, and Affect Dysregulation: The Complexity of Adaptation of Trauma." *Am J Psychiatry* 153, no. 7 Suppl (1996): 83-93.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.